Nippon Zoki Pharmaceutical Co., Ltd.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
1
Ending by 2030
Nov 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 9 to 20, 2026 · next Dec 9
- 1 fee due Jun 3, 2027The maintenance fee for Novel Prostaglandin Derivative (US 10,494,338) comes due Jun 3, 2027. Unpaid by Dec 3, 2027, it lapses early.
Recent changes
- 3 terms have ended since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,050,247 | Pharmaceutical composition for external use In force · From the USPTO record | In force | From the USPTO record | |
| US 9,011,849 | Ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and/or urination disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 8,987,486 | TRANS-2-Decenoic Acid Derivative and Pharmaceutical Agent Containing the Same In force · High confidence | In force | High confidence | |
| US 9,447,466 | Method for determination or evaluation of test substance In force · From the USPTO record | In force | From the USPTO record | |
| US 10,711,292 | Method for Promoting the Synthesis of Collagen and Proteoglycan in Chondrocytes In force · High confidence | In force | High confidence | |
| US 9,822,026 | Method and system for sludge treatment In force · From the USPTO record | In force | From the USPTO record | |
| US 11,529,374 | Extract and Formulation Including Extract In force · Medium confidence | In force | Medium confidence | |
| US 11,235,006 | Inhibiting or alleviating agent for Aβ-induced damage In force · From the USPTO record | In force | From the USPTO record | |
| US 11,324,704 | Sustained Drug Release Sheet for Treating Nerve Injury In force · High confidence | In force | High confidence | |
| US 10,494,338 | Novel Prostaglandin Derivative In force · High confidence | In force | High confidence |
Also on record, not counted in the 20: 1 patent in force now held by others · 57 lapsed for an unpaid fee · 73 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 7 abandoned · 19 no status recorded